Crescendo Biologics is a clinical-stage immuno-oncology company based in Cambridge, UK, that develops Humabody® VH-based multi‑functional therapeutics. Its lead proprietary programme, CB307, is a half-life extended CD137 x PSMA bispecific designed to activate tumour-specific T cells within the tumour microenvironment while avoiding systemic toxicity. The company uses a patented transgenic mouse platform to generate fully human VH domain building blocks (Humabody VH) that can be configured for novel pharmacology and improved biodistribution. CB307 is in an adaptive Phase 1b clinical trial with a monotherapy expansion cohort underway in PSMA+ metastatic castration-resistant prostate cancer and a planned pembrolizumab combination expansion cohort expected to start in Q3 2023. Beyond CB307, Crescendo has global discovery and development collaborations with Takeda and BioNTech and an exclusive worldwide licensing agreement with Zai Lab for ZL-1102, which is expected to enter global Phase 2 for psoriasis. The company recently secured additional financing to enable acceleration of its clinical programme. Crescendo Biologics develops potent, multi-functional Humabody® therapeutics for oncology, with a particular focus on novel targeted T‑cell engagers. Its lead programme, CB307, is designed to stimulate local activation of tumour-specific T‑cells and the company plans to advance CB307 into the clinic. The newly raised funds will also be used to expand Crescendo’s internal pipeline of Humabody-based products and pursue strategic partnerships. Crescendo has a collaboration with Takeda Pharma worth up to $790 million. The company is headquartered in Cambridge, England. The $70 million Series B will fund clinical entry and further platform development. Crescendo Biologics is a Cambridge, UK–based company focused on the discovery and development of human VH antibody fragment therapeutics. The company leverages its VH platform to develop topical biologics for psoriasis and multivalent products for oncology indications. Led by CEO Mike Romanos, Crescendo aims to advance multiple in-house development programmes. The firm raised additional capital in a Series A financing to support those programmes. The Series A was completed with a final close that increased the round size. No operating metrics were disclosed in the article. Crescendo Biologics is a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics. Led by CEO Mike Romanos, the company uses a VH fragment discovery platform to advance in-house development programmes in inflammation and oncology. It is establishing an internal pipeline that includes a topical biologic for psoriasis and multivalent products for oncology indications. In December 2013 Crescendo raised £17.5m ($28m) in a Series A financing to support these efforts. The company intends to use the funds to advance its inflammation and oncology programmes to the clinic. In conjunction with the funding, Rob Woodman of Imperial Innovations joined Crescendo’s board. Crescendo Biologics is a Cambridge, UK–based developer of antibody fragment technologies and a transgenic mouse platform. The platform is designed to rapidly generate high‑affinity human heavy chain antibodies that readily yield VH fragments with no requirement for humanisation. The company aims to apply this technology to create next‑generation targeted biological therapeutics based on fragment antibodies. It has appointed Dr Mike Romanos as CSO; he has extensive experience in biopharmaceutical R&D. Crescendo raised £4.5m in a seed funding round led by Sofinnova Partners, with Aitua, Avlar BioVentures and the Rainbow Seed Fund participating. The proceeds will be used to advance development of the platforms and to initiate the development of proprietary therapeutics.

Total raised

$140M

Funding rounds

5

Latest round

Equity

Latest activity

Jul 2023